Insider Selling: Entrada Therapeutics, Inc. (NASDAQ:TRDA) Insider Sells 1,409 Shares of Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) insider Natarajan Sethuraman sold 1,409 shares of Entrada Therapeutics stock in a transaction on Monday, November 11th. The stock was sold at an average price of $20.01, for a total value of $28,194.09. Following the completion of the transaction, the insider now owns 163,588 shares in the company, valued at $3,273,395.88. The trade was a 0.85 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Natarajan Sethuraman also recently made the following trade(s):

• On Wednesday, November 13th, Natarajan Sethuraman sold 2,700 shares of Entrada Therapeutics stock. The shares were sold at an average price of $20.04, for a total transaction of $54,108.00.
• On Wednesday, October 16th, Natarajan Sethuraman sold 600 shares of Entrada Therapeutics stock. The shares were sold at an average price of $18.00, for a total value of $10,800.00.
• On Monday, September 9th, Natarajan Sethuraman sold 2,642 shares of Entrada Therapeutics stock. The shares were sold at an average price of $15.09, for a total transaction of $39,867.78.
• On Friday, September 6th, Natarajan Sethuraman sold 600 shares of Entrada Therapeutics stock. The shares were sold at an average price of $15.24, for a total transaction of $9,144.00.

Entrada Therapeutics Price Performance

Entrada Therapeutics stock opened at $19.04 on Friday. The firm has a market cap of $712.48 million, a PE ratio of 11.97 and a beta of -0.26. Entrada Therapeutics, Inc. has a one year low of $10.75 and a one year high of $20.49. The stock’s fifty day moving average price is $16.62 and its two-hundred day moving average price is $15.85.

Entrada Therapeutics (NASDAQ:TRDA) last announced its quarterly earnings results on Tuesday, August 13th. The company reported $1.55 EPS for the quarter, beating analysts’ consensus estimates of $0.65 by $0.90. Entrada Therapeutics had a return on equity of 16.11% and a net margin of 25.53%. The company had revenue of $94.69 million during the quarter, compared to analysts’ expectations of $55.00 million. Sell-side analysts expect that Entrada Therapeutics, Inc. will post 1.07 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of TRDA. Martingale Asset Management L P boosted its holdings in Entrada Therapeutics by 36.9% during the third quarter. Martingale Asset Management L P now owns 37,923 shares of the company’s stock worth $606,000 after purchasing an additional 10,226 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Entrada Therapeutics by 34.7% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 14,156 shares of the company’s stock valued at $226,000 after acquiring an additional 3,644 shares during the period. Charles Schwab Investment Management Inc. increased its stake in shares of Entrada Therapeutics by 14.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 185,984 shares of the company’s stock worth $2,972,000 after purchasing an additional 23,643 shares during the last quarter. Massachusetts Financial Services Co. MA bought a new stake in shares of Entrada Therapeutics in the 3rd quarter worth approximately $1,109,000. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its stake in Entrada Therapeutics by 132.4% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 138,605 shares of the company’s stock valued at $2,215,000 after purchasing an additional 78,953 shares during the last quarter. 86.39% of the stock is owned by institutional investors.

Analyst Ratings Changes

TRDA has been the topic of a number of analyst reports. Oppenheimer increased their price target on shares of Entrada Therapeutics from $25.00 to $28.00 and gave the company an “outperform” rating in a research report on Wednesday, November 6th. HC Wainwright increased their price objective on shares of Entrada Therapeutics from $18.00 to $20.00 and gave the stock a “buy” rating in a research note on Wednesday, November 6th.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.